JP2017537621A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537621A5 JP2017537621A5 JP2017529013A JP2017529013A JP2017537621A5 JP 2017537621 A5 JP2017537621 A5 JP 2017537621A5 JP 2017529013 A JP2017529013 A JP 2017529013A JP 2017529013 A JP2017529013 A JP 2017529013A JP 2017537621 A5 JP2017537621 A5 JP 2017537621A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid sequence
- recombinant nucleic
- antibody
- chain polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical group 0.000 claims 52
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 43
- 238000000034 method Methods 0.000 claims 35
- 108090000765 processed proteins & peptides Proteins 0.000 claims 32
- 229920001184 polypeptide Polymers 0.000 claims 31
- 102000004196 processed proteins & peptides Human genes 0.000 claims 31
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 241000701022 Cytomegalovirus Species 0.000 claims 6
- 108091005804 Peptidases Proteins 0.000 claims 6
- 239000004365 Protease Substances 0.000 claims 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 238000003776 cleavage reaction Methods 0.000 claims 4
- 230000007017 scission Effects 0.000 claims 4
- 244000052769 pathogen Species 0.000 claims 3
- 230000001717 pathogenic effect Effects 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 235000005772 leucine Nutrition 0.000 claims 1
- 150000002614 leucines Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 239000000439 tumor marker Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022111396A JP2022160435A (ja) | 2014-12-01 | 2022-07-11 | Ｄｎａ抗体構築物及びその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086157P | 2014-12-01 | 2014-12-01 | |
| US62/086,157 | 2014-12-01 | ||
| US201562213166P | 2015-09-02 | 2015-09-02 | |
| US62/213,166 | 2015-09-02 | ||
| PCT/US2015/063174 WO2016089862A1 (en) | 2014-12-01 | 2015-12-01 | Dna antibody constructs and method of using same |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020201725A Division JP2021052776A (ja) | 2014-12-01 | 2020-12-04 | Ｄｎａ抗体構築物及びその使用方法 |
| JP2022111396A Division JP2022160435A (ja) | 2014-12-01 | 2022-07-11 | Ｄｎａ抗体構築物及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537621A JP2017537621A (ja) | 2017-12-21 |
| JP2017537621A5 true JP2017537621A5 (enExample) | 2019-01-17 |
| JP7268958B2 JP7268958B2 (ja) | 2023-05-08 |
Family
ID=56092325
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529013A Active JP7268958B2 (ja) | 2014-12-01 | 2015-12-01 | Ｄｎａ抗体構築物及びその使用方法 |
| JP2020201725A Pending JP2021052776A (ja) | 2014-12-01 | 2020-12-04 | Ｄｎａ抗体構築物及びその使用方法 |
| JP2022111396A Pending JP2022160435A (ja) | 2014-12-01 | 2022-07-11 | Ｄｎａ抗体構築物及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020201725A Pending JP2021052776A (ja) | 2014-12-01 | 2020-12-04 | Ｄｎａ抗体構築物及びその使用方法 |
| JP2022111396A Pending JP2022160435A (ja) | 2014-12-01 | 2022-07-11 | Ｄｎａ抗体構築物及びその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11278619B2 (enExample) |
| EP (1) | EP3226892A4 (enExample) |
| JP (3) | JP7268958B2 (enExample) |
| KR (1) | KR20170085131A (enExample) |
| CN (2) | CN107427566B (enExample) |
| AU (3) | AU2015355126B9 (enExample) |
| BR (1) | BR112017011556A2 (enExample) |
| CA (1) | CA2969214A1 (enExample) |
| MX (2) | MX2017007187A (enExample) |
| WO (1) | WO2016089862A1 (enExample) |
| ZA (1) | ZA201703710B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3080159A4 (en) * | 2013-12-13 | 2017-08-02 | The Trustees Of The University Of Pennsylvania | Dna antibody constructs and method of using same |
| CN107427566B (zh) * | 2014-12-01 | 2021-08-17 | 宾夕法尼亚大学理事会 | Dna抗体构建体及其使用方法 |
| EP3452504A4 (en) * | 2016-05-05 | 2020-07-29 | The Trustees of The University of Pennsylvania | MONOCLONAL DNA ANTIBODIES TARGETING INFLUENZA VIRUS |
| JP2019533993A (ja) * | 2016-09-19 | 2019-11-28 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ジカウイルスに対する新規ワクチンとジカウイルスに対する使用に向けたｄｎａ抗体構築物との組み合わせ |
| JP2020500033A (ja) * | 2016-11-07 | 2020-01-09 | ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー | ライム病に対する使用のためのｄｎａ抗体構築物 |
| JP2020511521A (ja) * | 2017-03-23 | 2020-04-16 | ディーエヌエーアールエックス | ｉｎ ｖｉｖｏでの核酸発現のためのシステム及び方法 |
| WO2018183294A1 (en) * | 2017-03-27 | 2018-10-04 | David Weiner | Dna antibody constructs for use against hiv |
| MX421249B (es) * | 2017-05-10 | 2025-02-10 | Wistar Inst | Constructos de anticuerpos de ácidos nucleicos optimizados |
| EP3635002A1 (en) * | 2017-06-08 | 2020-04-15 | Black Belt Therapeutics Limited | Cd38 modulating antibody |
| KR102770110B1 (ko) | 2017-08-16 | 2025-02-20 | 블랙 벨트 테라퓨틱스 리미티드 | Cd38 항체 |
| KR102770107B1 (ko) | 2017-08-16 | 2025-02-20 | 블랙 벨트 테라퓨틱스 리미티드 | Cd38 조정 항체 |
| US12162925B2 (en) * | 2017-09-15 | 2024-12-10 | The Wistar Institute Of Anatomy And Biology | DNA-encoded monoclonal antibodies targeting the Ebolavirus glycoprotein |
| AU2018345715A1 (en) * | 2017-10-06 | 2020-05-21 | The Wistar Institute Of Anatomy And Biology | DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer |
| WO2019152599A1 (en) * | 2018-01-31 | 2019-08-08 | The Wistar Institute Of Anatomy And Biology | Nucleic acid monoclonal antibodies targeting pcsk9 and methods of use |
| CN111253493B (zh) * | 2020-03-05 | 2021-03-23 | 武汉科技大学 | 一种靶向hiv病毒囊膜双位点的嵌合抗原受体及其表达载体和应用 |
| JP7765407B2 (ja) | 2020-05-14 | 2025-11-06 | イノビオ ファーマシューティカルズ，インコーポレイティド | 再発性呼吸器乳頭腫症のためのワクチン及びそれを使用する方法 |
| CN118725096B (zh) * | 2024-08-08 | 2025-02-07 | 兰州大学 | 一种ns1蛋白单克隆抗体及其应用 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US21579A (en) | 1858-09-21 | Rotary valve fob steam-engines | ||
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US5914109A (en) * | 1990-06-15 | 1999-06-22 | New York University | Heterohybridomas producing human monoclonal antibodies to HIV-1 |
| CA2134773A1 (en) | 1992-06-04 | 1993-12-09 | Robert J. Debs | Methods and compositions for in vivo gene therapy |
| US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| IL108449A (en) | 1993-01-26 | 2011-09-27 | Weiner David B | Assemblies and methods for delivery of genetic material |
| US5962428A (en) | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US6025158A (en) * | 1997-02-21 | 2000-02-15 | Genentech, Inc. | Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies |
| US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| DK1023107T3 (da) | 1997-04-03 | 2006-12-27 | Electrofect As | Fremgangsmåde til indgivelse af farmaceutiske præparater og nucleinsyrer i skeletmuskulaturen |
| US7276488B2 (en) | 1997-06-04 | 2007-10-02 | Oxford Biomedica (Uk) Limited | Vector system |
| HUP0004589A3 (en) | 1997-06-30 | 2003-08-28 | Centre Nat Rech Scient | Improved method for transferring nucleic acid into the striped muscle and combination therefor |
| US6697669B2 (en) | 1998-07-13 | 2004-02-24 | Genetronics, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
| US20030039635A1 (en) | 1998-09-30 | 2003-02-27 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US20030073613A1 (en) * | 2000-03-22 | 2003-04-17 | Mary Gerritsen | Angiogenisis associated proteins, and nucleic acids encoding the same |
| US20070037165A1 (en) | 2000-09-08 | 2007-02-15 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| JP3543326B2 (ja) | 2001-08-30 | 2004-07-14 | ソニー株式会社 | 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム |
| US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
| US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
| CA2504593C (en) | 2002-11-04 | 2016-08-09 | Advisys, Inc. | Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells |
| ES2748130T3 (es) | 2003-05-30 | 2020-03-13 | Vgxi Inc | Dispositivos y métodos para la producción de un biomaterial |
| CN1480215A (zh) | 2003-07-07 | 2004-03-10 | 叶新新 | Sars病毒抗原抗体复合疫苗及实验动物模型与方法 |
| SI1753871T1 (sl) | 2004-05-28 | 2016-01-29 | Agensys, Inc. | Protitelesa in sorodne molekule, ki se vežejo na psca proteine |
| EP1753871B1 (en) | 2004-05-28 | 2015-07-15 | Agensys, Inc. | Antibodies and related molecules that bind to psca proteins |
| US7714119B2 (en) | 2004-07-13 | 2010-05-11 | Biosante Pharmaceuticals, Inc. | AAV vector compositions and methods for enhanced expression of immunoglobulins using the same |
| KR20110050567A (ko) | 2004-07-22 | 2011-05-13 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| WO2006089231A2 (en) * | 2005-02-18 | 2006-08-24 | Medarex, Inc. | Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues |
| US20060216722A1 (en) | 2005-03-25 | 2006-09-28 | Christer Betsholtz | Glomerular expression profiling |
| BRPI0613784A2 (pt) | 2005-07-21 | 2011-02-01 | Abbott Lab | expressão de gene múltipla incluindo constructos sorf e métodos com poliproteìnas, pro-proteìnas e proteólise |
| EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| CA2598966A1 (en) | 2007-09-07 | 2009-03-07 | Institut Pasteur | Anti-chikungunya monoclonal antibodies and uses thereof |
| JP2009171880A (ja) | 2008-01-23 | 2009-08-06 | Yokohama City Univ | アルツハイマー病における次世代遺伝子治療法・免疫治療法の開発 |
| CN101970496B (zh) | 2008-03-14 | 2014-04-16 | 特朗斯吉有限公司 | 针对csf-1r的抗体 |
| JP5744719B2 (ja) | 2008-04-04 | 2015-07-08 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | チクングニヤウィルスタンパク質の共通配列、これをコードする核酸分子、並びにこれを使用する組成物および方法 |
| NZ592054A (en) | 2008-10-13 | 2013-06-28 | Inst Research In Biomedicine | Dengue virus neutralizing antibodies and uses thereof |
| SG177560A1 (en) | 2009-07-06 | 2012-03-29 | Hoffmann La Roche | Bi-specific digoxigenin binding antibodies |
| MY162326A (en) | 2009-07-13 | 2017-05-31 | Bharat Biotech Int Ltd | A composition useful as rotavirus vaccine and a method therefor |
| US20110045534A1 (en) | 2009-08-20 | 2011-02-24 | Cell Signaling Technology, Inc. | Nucleic Acid Cassette For Producing Recombinant Antibodies |
| EP2480572B1 (en) | 2009-09-25 | 2019-01-30 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Neutralizing antibodies to hiv-1 and their use |
| US8298820B2 (en) | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
| TWI627964B (zh) | 2010-07-09 | 2018-07-01 | 傑森疫苗防護公司 | 抗-人類呼吸道融合性病毒（ｒｓｖ）抗體及其使用方法 |
| US8637035B2 (en) | 2010-07-16 | 2014-01-28 | Academia Sinica | Anti-dengue virus antibodies |
| EP3536703B1 (en) | 2010-11-12 | 2021-05-26 | The Trustees of the University of Pennsylvania | Consensus prostate antigens, nucleic acid molecules encoding the same and uses thereof |
| WO2012106377A2 (en) | 2011-01-31 | 2012-08-09 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof |
| WO2012106578A1 (en) | 2011-02-04 | 2012-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc) |
| JP6091435B2 (ja) | 2011-02-22 | 2017-03-08 | カリフォルニア インスティチュート オブ テクノロジー | アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達 |
| US9540657B2 (en) | 2012-05-25 | 2017-01-10 | California Institute Of Technology | Expression of secreted and cell-surface polypeptides |
| BR112015013700A8 (pt) | 2012-12-13 | 2020-02-18 | Inovio Pharmaceuticals Inc | composição, sequência nucleotídica, anticorpo sintético, e, uso da composição |
| CN104812401B (zh) | 2012-12-13 | 2017-10-13 | 宾夕法尼亚大学理事会 | Wt1疫苗 |
| EP2934577A1 (en) * | 2012-12-19 | 2015-10-28 | Adimab, LLC | Multivalent antibody analogs, and methods of their preparation and use |
| EP3080159A4 (en) | 2013-12-13 | 2017-08-02 | The Trustees Of The University Of Pennsylvania | Dna antibody constructs and method of using same |
| CN107427566B (zh) * | 2014-12-01 | 2021-08-17 | 宾夕法尼亚大学理事会 | Dna抗体构建体及其使用方法 |
| HUE061078T2 (hu) * | 2018-07-31 | 2023-05-28 | Heidelberg Pharma Res Gmbh | PSMA elleni humanizált ellenanyagok |
-
2015
- 2015-12-01 CN CN201580075039.2A patent/CN107427566B/zh active Active
- 2015-12-01 JP JP2017529013A patent/JP7268958B2/ja active Active
- 2015-12-01 AU AU2015355126A patent/AU2015355126B9/en active Active
- 2015-12-01 KR KR1020177017224A patent/KR20170085131A/ko active Pending
- 2015-12-01 US US15/532,162 patent/US11278619B2/en active Active
- 2015-12-01 WO PCT/US2015/063174 patent/WO2016089862A1/en not_active Ceased
- 2015-12-01 EP EP15864627.3A patent/EP3226892A4/en not_active Withdrawn
- 2015-12-01 BR BR112017011556-5A patent/BR112017011556A2/en not_active Application Discontinuation
- 2015-12-01 CA CA2969214A patent/CA2969214A1/en active Pending
- 2015-12-01 MX MX2017007187A patent/MX2017007187A/es unknown
- 2015-12-01 CN CN202110892131.5A patent/CN114010802A/zh active Pending
-
2017
- 2017-05-30 ZA ZA201703710A patent/ZA201703710B/en unknown
- 2017-06-05 MX MX2023009421A patent/MX2023009421A/es unknown
-
2019
- 2019-04-08 AU AU2019202433A patent/AU2019202433A1/en not_active Abandoned
-
2020
- 2020-12-04 JP JP2020201725A patent/JP2021052776A/ja active Pending
-
2021
- 2021-03-12 AU AU2021201586A patent/AU2021201586A1/en not_active Abandoned
-
2022
- 2022-03-03 US US17/685,586 patent/US20230023093A1/en not_active Abandoned
- 2022-07-11 JP JP2022111396A patent/JP2022160435A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537621A5 (enExample) | ||
| JP2021087433A5 (enExample) | ||
| JP2016501535A5 (enExample) | ||
| JP7499813B2 (ja) | 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用 | |
| US20220169751A1 (en) | Multimeric ox40 binding molecules and uses thereof | |
| US20210388098A1 (en) | Multimeric cd137/4-1bb binding molecules and uses thereof | |
| JP2020114213A (ja) | 二重特異性ｔ細胞活性化抗原結合分子 | |
| JP2016053091A5 (enExample) | ||
| US20220098274A1 (en) | Engineered pd-1 variants | |
| HRP20150300T4 (hr) | Novi i snažni mhc-razred ii peptidi derivirani iz survivina i neurokana | |
| JP2019528683A (ja) | 多量体ｇｉｔｒ結合分子及びその使用 | |
| CN112004830B (zh) | 拮抗性pd-1、pd-l1和lag-3结合蛋白 | |
| JP2018512124A5 (enExample) | ||
| US20140234316A1 (en) | Vaccibodies targeted to cross-presenting dendritic cells | |
| WO2016127104A2 (en) | Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection | |
| NZ760008A (en) | Uti fusion proteins | |
| JP2023511652A (ja) | 鎖間システインが選択的にマッチングされた二重特異性抗体及びその使用 | |
| RU2020115161A (ru) | Днк моноклональных антител против ctla-4 для лечения и профилактики рака | |
| JPWO2020071554A5 (enExample) | ||
| CA3124688A1 (en) | Truncated multivalent multimers | |
| Dashtiahangar et al. | Anti-cancer immunotoxins, challenges, and approaches | |
| JPWO2020012486A5 (enExample) | ||
| US20220235135A1 (en) | Activating anti-gal9 binding molecules | |
| PE20211452A1 (es) | Nuevos receptores de celulas t modificados geneticamente y terapias inmunologicas que emplean los mismos | |
| CN106749661A (zh) | 抗psmp的单克隆抗体及其用途 |